Krystal Biotech, Inc. (FRA:4KB)

Market Cap	6.50B +44.9%
Revenue (ttm)	331.42M +33.9%
Net Income	174.45M +129.7%
EPS	5.83 +128.0%
Shares Out	n/a
PE Ratio	37.24
Forward PE	31.96
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	14
Open	222.80
Previous Close	240.20
Day's Range	222.80 - 222.80
52-Week Range	108.40 - 249.50
Beta	n/a
RSI	44.52
Earnings Date	Feb 17, 2026

About Krystal Biotech

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2016
• Employees: 295
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 4KB

Financial Performance

In 2025, Krystal Biotech's revenue was $389.13 million, an increase of 33.94% compared to the previous year's $290.52 million. Earnings were $204.83 million, an increase of 129.74%.

Financial numbers in USD